Examination concerning utility and safety of Cilostazol use in patients with PAD conplicated to CKD

Examination concerning utility and safety of Cilostazol use in patients with PAD conplicated to CKD - Examination concerning utility and safety of Cilostazol use in patients with PAD conplicated to CKD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003891

Enrollment

Registered

2010-07-15

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAD with CKD

Interventions

cilostazol aspirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with eGFR<60ml/min/1.73m2, or continues protein urea for three months or more 2)Patients with ABI<0.9, or TBI<0.7 3)Patients with agreement by document

Exclusion criteria

Exclusion criteria: 1)Nephrotic syndrome 2)active bleeding 3)allergy for cilostazol and aspirin 4)platelet dysfunction 5)age under 20y.o.

Design outcomes

Primary

Measure	Time frame
renal function(eGFR,cCRe), albuminuria and endothelial dysfunction	—

Secondary

Measure	Time frame
intima-media thickness(IMT), ABI,TBI,serum lipid marker	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026